|
|
ScanWatch, the first wearable to be cleared by the US Food and Drug Administration for measuring blood oxygen levels and detecting atrial fibrillation, can be in the marketplace within the US this November. ScanWatch's maker, French health expertise company Withings, said in a press launch that the wearable is the first to record each ECG and Sp02 measurements. Your Sp02 measurement tells you your blood oxygen degree. ECG (or EKG) measures the electrical impulses of your heart and can detect atrial fibrillation (AFib) or an irregular heartbeat. Withings CEO Mathieu Letombe stated in a launch. The watch has additionally been utilized in a study in Germany to watch COVID-19 patients, the company says. COVID-19 may cause respiratory problems as well as harm to the heart. ScanWatch is water-resistant up to 5 atmospheres and has a battery life of up to 30 days, per Withings. ScanWatch costs start at $277 (smaller watch) and $299 (bigger watch) and is available in black or white.
Check out my blog post BloodVitals tracker |
|
發表於